Herpes Simplex Encephalitis
Richard J. Whitley, Seng-Jaw Soong, Martin Hirsch et al. · New England Journal of Medicine · 1981
To learn more about the treatment of herpes simplex encephalitis with vidarabine, we conducted an uncontrolled study of 132 patients referred to 22 hospitals because of suspected disease. All had a brain biopsy and were started on vidarabine, but only 75 were diagnosed by isolation of virus from a brain-biopsy specimen. Cumulative mortality in the latter group was 39 per cent at one year. Other than therapy, levels of consciousness and age were the major variables that influenced outcome. Of 23 patients under 30 years of age who were lethargic at the initiation of therapy, two died and 16 returned to normal. Of 26 patients over 30 years of age who were lethargic at the outset, nine died and 10 returned to normal. Semicoma and coma were associated with worse outcomes, especially in older patients. Our data suggest that outcome is improved with treatment; they provide more support for the use of brain biopsy to diagnose the infection and indicate a need for better therapy.
Cited by 302 works. doi:10.1056/nejm198102053040602
Authors
References
- Regression Models and Life-Tables
- Adenine Arabinoside Therapy of Biopsy-Proved Herpes Simplex Encephalitis
- The Decision to Biopsy, Treat, or Wait in Suspected Herpes Encephalitis
- Failure of High Dose 5-Iodo-2′-Deoxyuridine in the Therapy of Herpes Simplex Virus Encephalitis
- The clinical management of suspected herpes virus encephalitis
- A Trial of Vidarabine for Cytomegalovirus Infection in Renal Transplant Patients
- Urinary Retention Probably Secondary to Herpes Genitalis
- Encephalitis and Ara-A: An Ethical Case Study
- Toxicity of Vidarabine
- Post-Infectious Encephalomyelitis after Successful Treatment of Herpes Simplex Encephalitis with Adenine Arabinoside